Overview
Majeed syndrome, also known as Chronic Recurrent Multifocal Osteomyelitis (CRMO) when considered in isolation, is a rare auto-inflammatory disorder predominantly affecting children and adolescents. Characterized by recurrent episodes of sterile bone inflammation, this condition can lead to significant morbidity due to bone pain, joint involvement, and potential spinal complications. The clinical presentation often mimics infectious osteomyelitis, leading to diagnostic challenges and delays, typically spanning about a year from symptom onset to accurate diagnosis. Early recognition and appropriate management are crucial to mitigate long-term complications and improve quality of life for affected individuals.
Epidemiology
Chronic Recurrent Multifocal Osteomyelitis (CRMO), a hallmark of Majeed syndrome, is exceedingly rare, with studies highlighting its infrequent occurrence. A comprehensive cohort study identified thirty-four children diagnosed with CRMO over a nine-year period, with an average age of symptom onset at 9.8 years and diagnosis at 10.9 years [PMID:25936788]. This age distribution underscores the pediatric predilection of the condition, primarily impacting the developmental stages of childhood and adolescence [PMID:23695372]. The rarity of CRMO necessitates heightened clinical suspicion, especially in pediatric populations presenting with recurrent bone pain and inflammatory symptoms, to avoid prolonged diagnostic odysseys. Epidemiological data remain limited, but the observed delay in diagnosis suggests a need for increased awareness among healthcare providers to facilitate timely intervention.
Clinical Presentation
CRMO typically manifests with a distinctive pattern of bone pain, often exacerbated at night, which can occur independently or alongside low-grade fever. The inflammatory process predominantly affects multiple sites, with involvement ranging from one to nearly twenty anatomical locations simultaneously [PMID:22359228]. Commonly affected regions include the metaphyseal areas of long bones, particularly the tibia and femur, as well as the clavicles and vertebral bodies [PMID:25936788]. In a significant proportion of cases, inflammatory arthritis accompanies bone involvement, affecting approximately half of the patients at diagnosis [PMID:25936788]. The lower extremities, especially the long bones, are frequently targeted, with spinal involvement adding complexity due to potential neurological implications. Recurrent episodes of pain reflect the multifocal nature of the disease, necessitating comprehensive imaging to assess the extent of bone inflammation and associated soft tissue involvement.
Diagnosis
Diagnosing CRMO requires a multifaceted approach due to its clinical overlap with infectious osteomyelitis. Magnetic Resonance Imaging (MRI) plays a pivotal role in diagnosis, offering superior sensitivity compared to conventional radiography and avoiding radiation exposure [PMID:22359228]. MRI not only delineates bone lesions but also evaluates soft tissue involvement, crucial for a comprehensive assessment of disease activity [PMID:22359228]. Laboratory investigations often reveal nonspecific markers of inflammation, such as mild elevations in white blood cell counts and erythrocyte sedimentation rates (ESR), though these can occasionally be normal [PMID:22359228]. Culturing blood and bone samples typically yields negative results, reinforcing the sterile nature of the inflammatory process [PMID:22359228]. The diagnostic journey frequently encounters delays, with an average lag of 12 months from symptom onset to definitive diagnosis in a notable cohort of 34 children [PMID:25936788]. Whole-body MRI can be particularly valuable in identifying asymptomatic lesions, aiding in early and accurate diagnosis [PMID:23695372]. In cases where differential diagnoses such as malignancy or infection are considered, bone biopsies may be indispensable to rule out other pathologies [PMID:23695372].
Differential Diagnosis
When evaluating a child with symptoms suggestive of CRMO, clinicians must consider several differential diagnoses to rule out infectious etiologies and other inflammatory conditions. Culture-negative osteomyelitis remains a critical differential, especially in the absence of positive microbiological findings [PMID:22359228]. A family history of psoriasis or inflammatory bowel disease (IBD) can provide supportive evidence for CRMO, as these conditions often coexist with auto-inflammatory syndromes [PMID:22359228]. Other conditions to consider include juvenile idiopathic arthritis, which can present with similar joint involvement, and malignancies affecting bone, where imaging and biopsy findings are crucial for differentiation [PMID:23695372]. The presence of multifocal bone lesions without systemic signs of infection or malignancy should heighten suspicion for CRMO, guiding further targeted diagnostic evaluations.
Management
Effective management of CRMO hinges on early recognition and tailored therapeutic approaches to alleviate symptoms and prevent long-term complications. Non-steroidal anti-inflammatory drugs (NSAIDs) are foundational in symptom management, providing relief in the majority of cases [PMID:25936788]. Corticosteroids (CSs) are frequently utilized, with a high utilization rate observed in clinical cohorts (82% of patients) [PMID:25936788]. Methotrexate (MTX) serves as a second-line option for those who do not respond adequately to NSAIDs or CSs, with a reported use in 38% of patients [PMID:25936788]. In more refractory cases, biologic agents targeting tumor necrosis factor (TNF)-α have shown utility, though their application is reserved for patients with severe or persistent symptoms [PMID:25936788]. Bisphosphonates represent another therapeutic avenue, particularly beneficial for patients with spinal involvement or those who do not respond to conventional treatments [PMID:23695372]. Clinicians must be vigilant to avoid unnecessary prolonged antibiotic therapy, recognizing CRMO as an auto-inflammatory condition rather than an infectious one, to prevent potential complications associated with antibiotic overuse [PMID:22359228].
Prognosis & Follow-up
The prognosis for children diagnosed with CRMO is generally favorable, with clinical remission achieved in a substantial majority (94%) of cases [PMID:25936788]. Notably, approximately 17% of these children maintain prolonged remission off medication for over 12 months, highlighting the potential for sustained disease control [PMID:25936788]. Regular follow-up is essential to monitor disease activity, manage flare-ups, and adjust treatment regimens as necessary. Long-term follow-up should include periodic imaging studies to detect any asymptomatic lesions and assess the need for continued or modified therapy. Given the potential for recurrence, ongoing clinical and radiological surveillance remains crucial to ensure optimal outcomes and minimize long-term skeletal complications.
Key Recommendations
References
1 Ferguson PJ, Sandu M. Current understanding of the pathogenesis and management of chronic recurrent multifocal osteomyelitis. Current rheumatology reports 2012. link 2 Walsh P, Manners PJ, Vercoe J, Burgner D, Murray KJ. Chronic recurrent multifocal osteomyelitis in children: nine years' experience at a statewide tertiary paediatric rheumatology referral centre. Rheumatology (Oxford, England) 2015. link 3 Costa-Reis P, Sullivan KE. Chronic recurrent multifocal osteomyelitis. Journal of clinical immunology 2013. link